Navigation Links
Data in NEJM shows Novartis drug Signifor® is first therapy to provide rapid, durable benefit for Cushing's disease patients in Phase III study
Date:3/7/2012

US Securities and Exchange Commission. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those anticipated, believed, estimated or expected. Novartis is providing the information in this press release as of this date and does not undertake any obligation to update any forward-looking statements contained in this press release as a result of new information, future events or otherwise.

About Novartis

Located in East Hanover, New Jersey, Novartis Pharmaceuticals Corporation is an affiliate of Novartis AG, which provides innovative healthcare solutions that address the evolving needs of patients and societies. Headquartered in Basel, Switzerland, Novartis offers a diversified portfolio to best meet these needs: innovative medicines, eye care, cost-saving generic pharmaceuticals, preventive vaccines and diagnostic tools, over-the-counter and animal health products. Novartis is the only global company with leading positions in these areas. In 2011, the Group's continuing operations achieved net sales of USD 58.6 billion, while approximately USD 9.6 billion (USD 9.2 billion excluding impairment and amortization charges) was invested in R&D throughout the Group. Novartis Group companies employ approximately 124,000 full-time-equivalent associates and operate in more than 140 countries around the world. For more information, please visit http://www.novartis.com.

Novartis is on Twitter. Sign up to follow @Novartis at http://twitter.com/novartis.

References

1.     Colao, A. A 12-Month Phase III Study of Pasireotide in Cushing's Disease. New Engl J Med. 2012; 366:32-42.
2.     National Endocrine and Metabolic Diseases Information Service. Cushing's Syndrome. Available at:

SOURCE Novartis Pharmaceuticals Corporation
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Iomai Trial Shows 100 Percent Immune Response in Elderly Subjects Vaccinated With Novel Travelers Diarrhea Patch Vaccine
2. Study Shows Combination Therapy Incorporating AVODART(R) and Tamsulosin Provides Continuous Symptom Improvement Over 2 Years
3. Largest Study to Date Shows Significant Reductions in Risks of Blood Clots and Reintervention With CYPHER(R) Sirolimus-eluting Coronary Stent Compared to Taxus Stent
4. Kosans Second-Generation Hsp90 Inhibitor, Alvespimycin, Shows 42% Clinical Benefit in Phase 1 HER2-Positive Metastatic Breast Cancer Trial
5. Study Shows Plasma-Derived Human Thrombin Equivalent to Bovine Thrombin in Achieving Hemostasis in Surgery
6. Cleveland Clinic Study Shows the Diabetes Drug Pioglitazone Reduces Risk of Death, Heart Attack and Stroke, but Increases Risk of Heart Failure
7. New Data From Large Safety Analysis of MYCAMINE Shows Favorable Clinical Safety Profile
8. Feeling Anxious or Distracted? New Research Shows a Cup of Tea Could Help
9. New Study Shows Once-Monthly Boniva(R) is as Clinically Effective as Once-Weekly Fosamax(R) at Increasing Bone Mineral Density in Postmenopausal Women With Osteoporosis
10. Study Shows Vasopressin Receptor Antagonist VAPRISOL(R) (Conivaptan Hydrochloride Injection) Significantly Increased Serum Sodium Concentration in Patients with Euvolemic & Hypervolemic Hyponatremia
11. Newly Published Phase II Study Shows the Investigational Drug Vandetanib Prolongs Progression-Free Survival in Patients with Advanced Non-Small Cell Lung Cancer (NSCLC)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/20/2014)...   Ventana Medical Systems, Inc.  (Ventana), a ... its VENTANA System for Primary Diagnosis 1 ... for routine pathology, including primary diagnosis with human ... software coupled with either the VENTANA iScan Coreo ... automated digital slide creation, case management and computer ...
(Date:8/20/2014)... LYNDHURST, N.J. , Aug. 20, 2014  Amerigen ... Amerigen Pharmaceuticals Co. Ltd., has received Chinese FDA ... Mecobalamin 0.5 mg Tablets into the ... of a marketing and distribution agreement with Sinochem ... product at its US FDA approved and China ...
(Date:8/20/2014)... , Aug. 20, 2014 Reportlinker.com ... available in its catalogue: The Market ... http://www.reportlinker.com/p02051938/The-Market-for-Medical-Devices-in-EMEA .html The European, Middle Eastern and ... medical devices. As part of its coverage, this ... concentrates on the EMEA medical device markets and ...
Breaking Medicine Technology:Full digitization of the anatomic pathology lab is here with the VENTANA System for Primary Diagnosis 2Full digitization of the anatomic pathology lab is here with the VENTANA System for Primary Diagnosis 3Amerigen Pharmaceuticals Ltd. announces that its Chinese subsidiary, Suzhou Amerigen Pharmaceuticals Co. Ltd., has received Chinese FDA (CFDA) approval and has subsequently launched its generic Mecobalamin 0.5 mg Tablets into the China domestic mark 2The Market for Medical Devices in EMEA 2The Market for Medical Devices in EMEA 3The Market for Medical Devices in EMEA 4The Market for Medical Devices in EMEA 5
(Date:8/20/2014)... NY (PRWEB) August 20, 2014 According ... filed on August 7 in the multicounty litigation (MCL) ... (IN RE DEPUY ASR HIP IMPLANTS LITIGATION; no. BER-L-3971-11), ... MCL have been dismissed without prejudice. The cases enumerated ... process of being resolved.” The Rottenstein Law Group LLP, ...
(Date:8/20/2014)... BCC Research ( http://www.bccresearch.com ) reveals ... DETECTORS: TECHNOLOGIES AND GLOBAL MARKETS , the global ... grow to $15.2 billion by 2019, with a ... Increasing industrialization is driving significant growth across ... range of industrial applications such as military and ...
(Date:8/20/2014)... Mateo, CA (PRWEB) August 20, 2014 ... newest product—the Really Little Green Pouch —to meet ... to feed babies and toddlers homemade foods. , ... Little Green Pouch co-founder Maggie Crawford. She continues, ... kids, to limit exposure to things like pesticides and ...
(Date:8/20/2014)... Pittsburgh, PA (PRWEB) August 20, 2014 ... to clean the mouth in an optimal manner without ... an inventor from Vacaville, Calif. , The patent-pending DR. ... the tongue and teeth thoroughly. It promotes good oral ... to use two different devices. Convenient, compact, affordable, eco-friendly ...
(Date:8/20/2014)... Tumour Research has been chosen by Plymouth University to ... launched in April 2009 to raise awareness of, and ... outcomes for brain tumour patients. , A range of ... funds for the charity, and members of staff and ... encouraged to donate, fundraise and volunteer. The involvement of ...
Breaking Medicine News(10 mins):Health News:350 NJ DePuy ASR Lawsuits Dismissed Pending Settlement Talks, Notes Rottenstein Law Group LLP 2Health News:Global Market for Photonic Sensors and Detectors to Reach $15.2 Billion in 2019 2Health News:Global Market for Photonic Sensors and Detectors to Reach $15.2 Billion in 2019 3Health News:Little Green Pouch Launches New Product to Help Health-conscious Parents Reduce Babies’ Eco-footprint 2Health News:Plymouth University chooses Brain Tumour Research as official charity 2
... Preventative Services Task Force,s (USPSTF) recommendation to no longer ... has begun to negatively affect the number of yearly ... the benefits of early detection. After the USPSTF delivered ... of Colorado saw a significant drop in mammograms in ...
... Mayo Clinic researchers have discovered two mutations responsible for ... ago. The researchers say their study -- appearing in ... neural pathway that may help understand a variety of ... now because of Next Generation genomic sequencing technology," says ...
... bursts of sleep in infants are linked with growth spurts, new ... daily sleep records for their infants (14 girls, nine boys), who ... researchers analyzed the total of 5,798 daily sleep records and also ... sleep, with the amount of sleep over a 24-hour period increasing ...
... can be quite jarring for a parent or caregiver to ... child roaming around the backseat free of their safety restraints. ... researchers reveals that most children who first unbuckle were age ... vehicle is in motionputting them at a 3.5-fold increased risk ...
... -- A drug commonly used to treat kidney cancer may ... study published in the May issue of the Journal ... the action of mammalian target of rapamycin (mTOR), a protein ... used to treat advanced renal cell carcinoma. But researchers ...
... Medical costs for children and teens with diabetes are six ... States, a new study finds. Researchers from the U.S. ... made in 2007 for nearly 50,000 youth aged 19 and ... youth with diabetes were $9,061, compared with $1,468 for those ...
Cached Medicine News:Health News:New studies show negative effects from revised mammography recommendation for women, ages 40-49 2Health News:Mayo Clinic finds new genetic cause of neurodegeneration 2Health News:Extra Sleep in Infants Seems to Signal Growth Spurts 2Health News:Little fingers, big trouble: Yale study sheds light on child self-unbuckling 2Health News:Renal cancer drug temsirolimus shows promise against mesothelioma 2
... A fixed pipette is ... a single volume. Fixed volume ... and advantages as other Finnpipette ... design, Super blow-out (1-40ul), Soft-touch ...
... The new Finnpipette Focus ... specifically to combine ergonomics with ... interchangeable handle plate offers a ... sizes. The new shorter tip ...
5L...
... is precision, ergonomics, and value!, ... with soft non-slip, contoured handle , ... light plunger spring action , Completely ... without the need for recalibration , ...
Medicine Products: